Concepedia

Publication | Open Access

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer

30

Citations

20

References

2019

Year

Abstract

A diverse population of patients with mPAC that progressed on gemcitabine-based therapy benefited from nal-IRI+5-FU/LV versus 5-FU/LV, potentially helping guide treatment decisions for challenging cases.

References

YearCitations

Page 1